This study tests a new combination pill (FDC laroprovstat/rosuvastatin) to lower LDL-C, a type of bad cholesterol, in people who haven't tried cholesterol-lowering treatments (LLT) before. **Laroprovstat** is a drug that helps reduce LDL-C in the blood. **Rosuvastatin** is a commonly used medicine to lower cholesterol. **FDC** stands for Fixed-Dose Combination, meaning both drugs are in one pill. The study checks if this combination works better than taking each medicine separately or taking a placebo (a pill with no active medicine).

• Study Length: This is a Phase III study, indicating it's in the final stages before approval.
• Eligibility: Participants must be 18 or older, have low estimated heart disease risk, and not have used LLT recently.
• Exclusion: People of Asian origin, those with severe uncontrolled health issues, or who can't tolerate statins cannot join.